NDATOPICALOINTMENT
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
ADQUEY (difamilast) by Acrotech Biopharma is phosphodiesterase 4 inhibitors [moa]. Approved for phosphodiesterase 4 inhibitor [epc]. First approved in 2026.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADQUEY (difamilast) is a topical phosphodiesterase 4 inhibitor ointment approved in February 2026 for inflammatory skin conditions. The drug works by inhibiting PDE4, reducing inflammatory cytokine production in dermatological applications. It represents a non-systemic alternative to oral PDE4 inhibitors in the dermatology space.
Launch10.2 years to LOE
Early-stage launch product with potential for rapid team expansion as market adoption accelerates in dermatology.
Mechanism of Action
Phosphodiesterase 4 Inhibitors
Pharmacologic Class:
Phosphodiesterase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
Started Oct 2022
153 enrolled
Atopic Dermatitis
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
Started Sep 2022
542 enrolled
Atopic Dermatitis
Career Relevance
Working on ADQUEY offers entry or mid-career opportunity in a newly launched specialty dermatology product with significant upside as market adoption ramps. The 10-year exclusivity window and small but focused team structure provide career stability and visibility in a high-growth niche.
Worked on ADQUEY at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.